Australia - inglés - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risedronate sodium hemipentahydrate, quantity: 40.5 mg (equivalent: risedronate sodium, qty 35 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; iron oxide red; macrogol 8000; magnesium stearate; hyprolose; lactose; titanium dioxide; hypromellose; crospovidone; iron oxide yellow - - treatment of osteoporosis. - treatment of glucocorticoid-induced osteoporosis. - preservation of bone mineral density in patients on long term corticosteroid therapy.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - risedronate sodium hemipentahydrate 35mg (as hemipentahydrate) - film coated tablet - 35 mg - active: risedronate sodium hemipentahydrate 35mg (as hemipentahydrate) excipient: crospovidone instacoat universal orange icg-u-10149 lactose monohydrate magnesium stearate microcrystalline cellulose povidone purified water   - treatment of osteoporosis.

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

dr reddy's new zealand limited - risedronate sodium hemipentahydrate 5mg (as hemipentahydrate) - film coated tablet - 5 mg - active: risedronate sodium hemipentahydrate 5mg (as hemipentahydrate) excipient: crospovidone instacoat universal yellow icg-u-10146 lactose monohydrate magnesium stearate microcrystalline cellulose povidone purified water   - treatment of osteoporosis.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

bafna pharmaceuticals pty ltd - risedronate sodium hemipentahydrate, quantity: 172.1 mg (equivalent: risedronate sodium, qty 150 mg) - tablet, film coated - excipient ingredients: crospovidone; colloidal anhydrous silica; microcrystalline cellulose; mannitol; magnesium stearate; titanium dioxide; hypromellose; macrogol 8000; sunset yellow fcf aluminium lake; polydextrose; macrogol 400; indigo carmine aluminium lake - ? treatment of osteoporosis.,? treatment of glucocorticoid-induced osteoporosis.,? preservation of bone mineral density in patients on long term corticosteroid therapy.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risedronate sodium hemipentahydrate, quantity: 86.7 mg - tablet, film coated - excipient ingredients: hypromellose; titanium dioxide; macrogol 8000; iron oxide red; colloidal anhydrous silica; hyprolose; magnesium stearate; crospovidone; lactose - the treatment of osteoporosis,the treatment of glucocorticoid-induced osteoporosis,the preservation of bone-mineral density in patients on long term corticosteroid therapy

Australia - inglés - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risedronate sodium hemipentahydrate, quantity: 86.7 mg - tablet, film coated - excipient ingredients: hyprolose; iron oxide red; colloidal anhydrous silica; magnesium stearate; hypromellose; macrogol 8000; crospovidone; titanium dioxide; lactose - the treatment of osteoporosis,the treatment of glucocorticoid-induced osteoporosis,the preservation of bone-mineral density in patients on long term corticosteroid therapy

Nueva Zelanda - inglés - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - risedronate sodium hemipentahydrate 40.2mg equivalent to risedronate sodium 35 mg and = risedronic acid 32.5 mg - film coated tablet - 35 mg - active: risedronate sodium hemipentahydrate 40.2mg equivalent to risedronate sodium 35 mg and = risedronic acid 32.5 mg excipient: crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose opadry orange 03b32322 - · treatment of osteoporosis · treatment of glucocorticoid-induced osteoporosis · treatment of postmenopausal osteoporosis

Australia - inglés - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risedronate sodium hemipentahydrate, quantity: 40.5 mg (equivalent: risedronate sodium, qty 35 mg) - tablet, film coated - excipient ingredients: hypromellose; titanium dioxide; macrogol 8000; lactose; magnesium stearate; iron oxide red; crospovidone; hyprolose; colloidal anhydrous silica; iron oxide yellow - - treatment of osteoporosis. - treatment of glucocorticoid-induced osteoporosis. - preservation of bone mineral density in patients on long term corticosteroid therapy.

Australia - inglés - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - risedronate sodium hemipentahydrate, quantity: 173.4 mg - tablet, film coated - excipient ingredients: lactose; hyprolose; hypromellose; crospovidone; titanium dioxide; magnesium stearate; colloidal anhydrous silica; macrogol 8000; monobasic sodium phosphate dihydrate; dibasic sodium phosphate; indigo carmine aluminium lake; monobasic sodium phosphate monohydrate - the treatment of osteoporosis,the treatment of glucocorticoid-induced osteoporosis,the preservation of bone-mineral density in patients on long term corticosteroid therapy

Australia - inglés - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - risedronate sodium hemipentahydrate, quantity: 86.7 mg - tablet, film coated - excipient ingredients: crospovidone; colloidal anhydrous silica; titanium dioxide; iron oxide red; magnesium stearate; hyprolose; macrogol 8000; hypromellose; lactose - the treatment of osteoporosis,the treatment of glucocorticoid-induced osteoporosis,the preservation of bone-mineral density in patients on long term corticosteroid therapy